Loading...
XLON
ONC
Market cap17kUSD
Mar 17, Last price  
0.01GBP
Name

Oncimmune Holdings PLC

Chart & Performance

D1W1MN
No data to show
P/E
0.31
P/S
1.11
EPS
0.04
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
-14.87%
Revenues
1m
-70.15%
1,535,0001,057,0001,345,000430,000215,000240,000171,000509,0003,722,0003,859,0001,152,000
Net income
4m
P
-3,016,000-1,412,000-2,013,000-8,442,000-5,023,000-6,310,000-8,012,000-8,459,000-4,628,000-9,512,0004,104,000
CFO
-7m
L+9.34%
-2,985,000-2,149,000-1,520,000-3,179,000-4,279,000-6,101,000-7,359,000-8,903,000-4,527,000-6,211,000-6,791,000

Profile

Oncimmune Holdings plc develops and commercializes technologies that enable cancer diagnosis in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, a immunodiagnostic test for detecting and identifying lung cancer. The company also develops SeroTag, a platform that is used to discover and validate biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc was incorporated in 2015 and is based in Nottingham, the United Kingdom.
URL
https://oncimmune.com/
IPO date
May 18, 2016
Employees
52
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2023‑082022‑052021‑052020‑052019‑052018‑052017‑052016‑05
Income
Revenues
1,152
-70.15%
Cost of revenue
5,394
Unusual Expense (Income)
NOPBT
(4,242)
NOPBT Margin
Operating Taxes
223
Tax Rate
NOPAT
(4,465)
Net income
4,104
-143.15%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,095
BB yield
-12.44%
Debt
Debt current
332
Long-term debt
4,969
Deferred revenue
57
Other long-term liabilities
1,284
Net debt
2,575
Cash flow
Cash from operating activities
(6,791)
CAPEX
(31)
Cash from investing activities
11,583
Cash from financing activities
(3,015)
FCF
(2,846)
Balance
Cash
3,209
Long term investments
(483)
Excess cash
2,668
Stockholders' equity
(42,026)
Invested Capital
49,268
ROIC
ROCE
EV
Common stock shares outstanding
72,575
Price
0.23
-76.21%
Market cap
16,837
-73.25%
EV
19,412
EBITDA
(3,977)
EV/EBITDA
Interest
516
Interest/NOPBT